UNICREDIT BANK/CALL/BIOGEN IDEC/220/0.1/18.06.25 | Real-time BOERSE MUENCHEN 08:42:16 03/07/2024 BST | ||
| 3.72 EUR | 0.00% |
|
| Current month | -7.23% | ||
| 1 month | -3.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 3.72 | 0.00% |
| 02/07/24 | 3.72 | -10.36% |
| 01/07/24 | 4.15 | +3.49% |
| 28/06/24 | 4.01 | +0.50% |
| 27/06/24 | 3.99 | +8.42% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 08:42 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4FKT |
| ISIN | DE000HD4FKT7 |
| Date issued | 08/04/2024 |
| Strike | 220 $ |
| Maturity | 18/06/2025 (351 Days) |
| Parity | 10 : 1 |
| Emission price | 2.94 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.58 € |
|---|---|
| Lowest since issue | 2.26 € |
| Spread | 0.08 € |
| Spread % | 2.14% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
228.8
USD
Average target price
283.2
USD
Spread / Average Target
+23.75%
- Stock Market
- Warrants
- Warrant
